XML 75 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration Agreements,License Agreement and Revenues - Roll-forward of Related Contract Liabilities (Detail)
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
AstraZeneca Agreements [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 $ (171,516)
Additions (77,195)
Currency Translation and Other 1,898
Recognized as Revenue 71,167
Balance at December 31, 2022 (175,646)
Product [Member] | Direct Sales [Member] | Contract Liabilities [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (3,176)
Additions (653)
Deduction 3,222
Currency Translation and Other 217
Balance at December 31, 2022 (390)
Drug Product Revenue [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (39,036)
Additions (74,634)
Recognized as Revenue 619
Reclassified to accrued liability / accounts payable 72,748
Balance at December 31, 2022 (40,303)
Drug Product Revenue [Member] | AstraZeneca Agreements [Member] | U.S. [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (11,171)
Additions 0
Recognized as Revenue 0
Reclassified to accrued liability / accounts payable 11,171
Balance at December 31, 2022 0
Drug Product Revenue [Member] | Astellas Agreement | Japan [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (1,974)
Additions (2,226)
Recognized as Revenue 0
Reclassified to accrued liability / accounts payable 4,200
Balance at December 31, 2022 0
Drug Product Revenue [Member] | Astellas Agreement | Europe [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (25,891)
Additions (72,408)
Recognized as Revenue 619
Reclassified to accrued liability / accounts payable 57,377
Balance at December 31, 2022 $ (40,303)